Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Hydrochloride Liposome in Advanced Gastric Carcinoma
NCT04718402Phase 1Terminated
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Mar 2021
- Primary completion
- May 2022
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitoxantrone hydrochloride liposome in Gastric carcinoma (GC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Adverse Events up to 36 months. Started Mar 2021; status: terminated.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
Gastric carcinoma (GC)
Beyond the preview
Go deeper on NCT04718402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718402.